Systemic therapy for sarcomatoid renal cell carcinoma

Lance C. Pagliaro; Nizar Tannir; Kanishka Sircar; Eric Jonasch

doi:10.1586/era.11.39

Systemic therapy for sarcomatoid renal cell carcinoma

Lance C. Pagliaro, Nizar Tannir, Kanishka Sircar, Eric Jonasch

Medical Oncology

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Renal cell carcinoma (RCC) is the most common malignant neoplasm of the kidney, and sarcomatoid RCC is an aggressive and lethal variant. Sarcomatoid features can be seen in all types of RCC and do not constitute a separate histologic type. No cellular or genetic biomarker for the sarcomatoid variant has yet been discovered. Most systemic therapies developed for metastatic RCC are less effective in sarcomatoid RCC, although some of the cytotoxic drugs may actually be more effective for sarcomatoid RCC because of its rapid rate of proliferation. Several ongoing prospective clinical trials are investigating new drug combinations for this disease.

Original language	English (US)
Pages (from-to)	913-920
Number of pages	8
Journal	Expert review of anticancer therapy
Volume	11
Issue number	6
DOIs	https://doi.org/10.1586/era.11.39
State	Published - Jun 2011

Keywords

bevacizumab
chemotherapy
drug therapy
immunotherapy
kidney neoplasm
sarcomatoid neoplasm

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

Access to Document

10.1586/era.11.39

Cite this

@article{db0f56ef7a5d40d7b2f5ea99bbb7a983,

title = "Systemic therapy for sarcomatoid renal cell carcinoma",

abstract = "Renal cell carcinoma (RCC) is the most common malignant neoplasm of the kidney, and sarcomatoid RCC is an aggressive and lethal variant. Sarcomatoid features can be seen in all types of RCC and do not constitute a separate histologic type. No cellular or genetic biomarker for the sarcomatoid variant has yet been discovered. Most systemic therapies developed for metastatic RCC are less effective in sarcomatoid RCC, although some of the cytotoxic drugs may actually be more effective for sarcomatoid RCC because of its rapid rate of proliferation. Several ongoing prospective clinical trials are investigating new drug combinations for this disease.",

keywords = "bevacizumab, chemotherapy, drug therapy, immunotherapy, kidney neoplasm, sarcomatoid neoplasm",

author = "Pagliaro, {Lance C.} and Nizar Tannir and Kanishka Sircar and Eric Jonasch",

year = "2011",

month = jun,

doi = "10.1586/era.11.39",

language = "English (US)",

volume = "11",

pages = "913--920",

journal = "Expert review of anticancer therapy",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "6",

}

TY - JOUR

T1 - Systemic therapy for sarcomatoid renal cell carcinoma

AU - Pagliaro, Lance C.

AU - Tannir, Nizar

AU - Sircar, Kanishka

AU - Jonasch, Eric

PY - 2011/6

Y1 - 2011/6

N2 - Renal cell carcinoma (RCC) is the most common malignant neoplasm of the kidney, and sarcomatoid RCC is an aggressive and lethal variant. Sarcomatoid features can be seen in all types of RCC and do not constitute a separate histologic type. No cellular or genetic biomarker for the sarcomatoid variant has yet been discovered. Most systemic therapies developed for metastatic RCC are less effective in sarcomatoid RCC, although some of the cytotoxic drugs may actually be more effective for sarcomatoid RCC because of its rapid rate of proliferation. Several ongoing prospective clinical trials are investigating new drug combinations for this disease.

AB - Renal cell carcinoma (RCC) is the most common malignant neoplasm of the kidney, and sarcomatoid RCC is an aggressive and lethal variant. Sarcomatoid features can be seen in all types of RCC and do not constitute a separate histologic type. No cellular or genetic biomarker for the sarcomatoid variant has yet been discovered. Most systemic therapies developed for metastatic RCC are less effective in sarcomatoid RCC, although some of the cytotoxic drugs may actually be more effective for sarcomatoid RCC because of its rapid rate of proliferation. Several ongoing prospective clinical trials are investigating new drug combinations for this disease.

KW - bevacizumab

KW - chemotherapy

KW - drug therapy

KW - immunotherapy

KW - kidney neoplasm

KW - sarcomatoid neoplasm

UR - http://www.scopus.com/inward/record.url?scp=79959801387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959801387&partnerID=8YFLogxK

U2 - 10.1586/era.11.39

DO - 10.1586/era.11.39

M3 - Review article

C2 - 21707288

AN - SCOPUS:79959801387

SN - 1473-7140

VL - 11

SP - 913

EP - 920

JO - Expert review of anticancer therapy

JF - Expert review of anticancer therapy

IS - 6

ER -

Systemic therapy for sarcomatoid renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this